GSK Jan 2025 45.000 call
| Previous close | 0.9000 |
| Open | 1.0000 |
| Bid | 0.8000 |
| Ask | 1.1000 |
| Strike | 45.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.0000 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 164 |
- Motley Fool
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.
- Business Wire
GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
- Zacks
Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
